期刊
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
卷 184, 期 -, 页码 325-338出版社
ELSEVIER
DOI: 10.1016/j.ijbiomac.2021.06.014
关键词
PEGylated chitosan nanoparticle; Anti-HER2 monoclonal antibody; Doxorubicin targeted drug delivery
资金
- American University in Cairo, Egypt
Breast cancer is a top chronic and life-threatening disease worldwide. Nano-drug therapeutic systems using biodegradable chitosan nanoparticles (CSNPs) have shown efficacy in providing selective and sustained release of drugs within the breast tumor microenvironment. Functionalizing CSNPs with breast cancer-specific monoclonal antibodies (mAb) has demonstrated high cytotoxicity against cancer cells.
Breast cancer has been one of the top chronic and life-threatening diseases worldwide. Nano-drug therapeutic systems have proved their efficacy as a selective treatment compared to the traditional ones that are associated with serious adverse effects. Here, biodegradable chitosan nanoparticles (CSNPs) were synthesized to provide selective and sustained release of doxorubicin (DOX) within the breast tumor microenvironment. CSNPs surface was modified using Polyethylene glycol (PEG) to enhance their blood circulation timing. To provide high drug selectivity, CSNPs functionalized with two different types of breast cancer-specific monoclonal antibodies (mAb); anti-human mammaglobin (Anti-hMAM) and anti-human epidermal growth factor (Anti-HER2). Anti-hMAM PEGylated DOX loaded CSNPs and Anti-HER2 PEGylated DOX loaded CSNPs nano-formulations were the most cytotoxic against MCF-7 cancer cells than L-929 normal cells compared to free DOX. Finally, we believe that dose-dependent system toxicity of freely ingested DOX can be managed with such targeted nano-formulated drug delivery platforms.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据